Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation - Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details)

Stock-Based Compensation - Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) $ / shares shares
Non vested Shares Granted \| shares	1,422,658
Non vested Shares Vested \| shares	(599,182)
Non vested Shares Forfeited \| shares
Non vested Weighted Average Grant Date Fair Value Granted \| $ / shares	$ 1.49
Non vested Weighted Average Grant Date Fair Value Vested \| $ / shares	1.61
Non vested Weighted Average Grant Date Fair Value Forfeited \| $ / shares
Restricted Stock Units (RSUs) [Member]
Non vested Shares beginning balance \| shares	102,369
Non vested Shares Granted \| shares
Non vested Shares Vested \| shares	(34,019)
Non vested Shares Forfeited \| shares	(350)
Non vested Shares ending balance \| shares	68,000
Non vested Weighted Average Grant Date Fair Value beginning balance \| $ / shares	$ 2.49
Non vested Weighted Average Grant Date Fair Value Granted \| $ / shares
Non vested Weighted Average Grant Date Fair Value Vested \| $ / shares	2.49
Non vested Weighted Average Grant Date Fair Value Forfeited \| $ / shares	2.30
Non vested Weighted Average Grant Date Fair Value Ending balance \| $ / shares	$ 2.49
Non vested Average Remaining Vesting Period Beginning balance	2 years 1 month 20 days
Non vested Average Remaining Vesting Period Ending balance	7 months 21 days
Nonvested Aggregate Intrinsic Value Beginning balance \| $	$ 450
Nonvested Aggregate Intrinsic Value Granted \| $
Nonvested Aggregate Intrinsic Value Vested \| $
Nonvested Aggregate Intrinsic Value Forfeited \| $
Nonvested Aggregate Intrinsic Value Ending balance \| $	$ 69